Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
Abstract Background This study aims to evaluate the efficacy and safety of camrelizumab in combination with chemotherapy as a second-line treatment for patients with locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC). Methods In this retrospective, single-center obs...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-025-03690-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823862153067626496 |
|---|---|
| author | Yinfang Gu Xiaofang Zou Junlin Zhu Guowu Wu |
| author_facet | Yinfang Gu Xiaofang Zou Junlin Zhu Guowu Wu |
| author_sort | Yinfang Gu |
| collection | DOAJ |
| description | Abstract Background This study aims to evaluate the efficacy and safety of camrelizumab in combination with chemotherapy as a second-line treatment for patients with locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC). Methods In this retrospective, single-center observational study, we collected medical records of patients with locally advanced, recurrent, or metastatic ESCC who received either camrelizumab combined with chemotherapy or chemotherapy alone as second-line treatment between July 1, 2019, and May 31, 2023. We evaluated short-term efficacy, including overall response rate (ORR) and disease control rate (DCR), as well as survival outcomes, including progression-free survival (PFS) and overall survival (OS). Safety was also assessed. Additionally, factors influencing OS in ESCC patients were analyzed. Results A total of 60 patients with locally advanced, recurrent, or metastatic ESCC were included, with 30 receiving camrelizumab combined with chemotherapy and 30 receiving chemotherapy alone as second-line treatment. There were no statistically significant differences in ORR (33.33% vs. 13.33%) and DCR (73.33% vs. 56.67%) between the combination therapy and chemotherapy-alone groups (P > 0.05). However, the median PFS was significantly longer in the combination therapy group compared to the chemotherapy group (4.7 months vs. 3.4 months, P = 0.048). Additionally, the median OS was significantly improved in the combination therapy group compared to the chemotherapy group (11.7 months vs. 6.5 months, P = 0.003). Age and history of radical surgery were significantly associated with OS in patients receiving camrelizumab combined with chemotherapy as second-line treatment (P < 0.05). Conclusion Second-line treatment with camrelizumab combined with chemotherapy is well-tolerated and associated with favorable oncological outcomes in patients with locally advanced, recurrent, or metastatic ESCC. Furthermore, younger patients and those who have undergone radical surgery may derive greater benefit from camrelizumab combined with chemotherapy as a second-line treatment. |
| format | Article |
| id | doaj-art-434887483a634cc89e436ecf325604f7 |
| institution | Kabale University |
| issn | 1477-7819 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj-art-434887483a634cc89e436ecf325604f72025-02-09T12:39:51ZengBMCWorld Journal of Surgical Oncology1477-78192025-02-0123111510.1186/s12957-025-03690-9Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinomaYinfang Gu0Xiaofang Zou1Junlin Zhu2Guowu Wu3Department of Oncology, Cancer Center, Meizhou People’s Hospital (Huangtang Hospital, Meizhou Academy of Medical SciencesDepartment of Oncology, Cancer Center, Meizhou People’s Hospital (Huangtang Hospital, Meizhou Academy of Medical SciencesDepartment of Oncology, Cancer Center, Meizhou People’s Hospital (Huangtang Hospital, Meizhou Academy of Medical SciencesDepartment of Oncology, Cancer Center, Meizhou People’s Hospital (Huangtang Hospital, Meizhou Academy of Medical SciencesAbstract Background This study aims to evaluate the efficacy and safety of camrelizumab in combination with chemotherapy as a second-line treatment for patients with locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC). Methods In this retrospective, single-center observational study, we collected medical records of patients with locally advanced, recurrent, or metastatic ESCC who received either camrelizumab combined with chemotherapy or chemotherapy alone as second-line treatment between July 1, 2019, and May 31, 2023. We evaluated short-term efficacy, including overall response rate (ORR) and disease control rate (DCR), as well as survival outcomes, including progression-free survival (PFS) and overall survival (OS). Safety was also assessed. Additionally, factors influencing OS in ESCC patients were analyzed. Results A total of 60 patients with locally advanced, recurrent, or metastatic ESCC were included, with 30 receiving camrelizumab combined with chemotherapy and 30 receiving chemotherapy alone as second-line treatment. There were no statistically significant differences in ORR (33.33% vs. 13.33%) and DCR (73.33% vs. 56.67%) between the combination therapy and chemotherapy-alone groups (P > 0.05). However, the median PFS was significantly longer in the combination therapy group compared to the chemotherapy group (4.7 months vs. 3.4 months, P = 0.048). Additionally, the median OS was significantly improved in the combination therapy group compared to the chemotherapy group (11.7 months vs. 6.5 months, P = 0.003). Age and history of radical surgery were significantly associated with OS in patients receiving camrelizumab combined with chemotherapy as second-line treatment (P < 0.05). Conclusion Second-line treatment with camrelizumab combined with chemotherapy is well-tolerated and associated with favorable oncological outcomes in patients with locally advanced, recurrent, or metastatic ESCC. Furthermore, younger patients and those who have undergone radical surgery may derive greater benefit from camrelizumab combined with chemotherapy as a second-line treatment.https://doi.org/10.1186/s12957-025-03690-9CamrelizumabChemotherapyEsophageal squamous cell carcinomaEfficacySafety |
| spellingShingle | Yinfang Gu Xiaofang Zou Junlin Zhu Guowu Wu Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma World Journal of Surgical Oncology Camrelizumab Chemotherapy Esophageal squamous cell carcinoma Efficacy Safety |
| title | Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma |
| title_full | Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma |
| title_fullStr | Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma |
| title_full_unstemmed | Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma |
| title_short | Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma |
| title_sort | efficacy and safety of camrelizumab combined with chemotherapy as second line treatment for locally advanced recurrent or metastatic esophageal squamous cell carcinoma |
| topic | Camrelizumab Chemotherapy Esophageal squamous cell carcinoma Efficacy Safety |
| url | https://doi.org/10.1186/s12957-025-03690-9 |
| work_keys_str_mv | AT yinfanggu efficacyandsafetyofcamrelizumabcombinedwithchemotherapyassecondlinetreatmentforlocallyadvancedrecurrentormetastaticesophagealsquamouscellcarcinoma AT xiaofangzou efficacyandsafetyofcamrelizumabcombinedwithchemotherapyassecondlinetreatmentforlocallyadvancedrecurrentormetastaticesophagealsquamouscellcarcinoma AT junlinzhu efficacyandsafetyofcamrelizumabcombinedwithchemotherapyassecondlinetreatmentforlocallyadvancedrecurrentormetastaticesophagealsquamouscellcarcinoma AT guowuwu efficacyandsafetyofcamrelizumabcombinedwithchemotherapyassecondlinetreatmentforlocallyadvancedrecurrentormetastaticesophagealsquamouscellcarcinoma |